| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/29/2002 | WO2002066040A2 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus |
| 08/29/2002 | WO2002066038A1 Treatment of refractory tumors using epothilone derivatives |
| 08/29/2002 | WO2002066035A2 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/29/2002 | WO2002066034A1 Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors |
| 08/29/2002 | WO2002066033A1 Epothilone derivatives for the treatment of refractory tumors |
| 08/29/2002 | WO2002066028A2 Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids |
| 08/29/2002 | WO2002066027A1 Agent for inhibiting tumour cells |
| 08/29/2002 | WO2002066021A2 Protein kinase d inhibitors and protein kinase 2 inhibitors as agents for inhibiting tumour cells and for stimulating angiogenesis |
| 08/29/2002 | WO2002066019A2 Cancer treatment |
| 08/29/2002 | WO2002066018A2 Transdermal therapeutic system containing testosterone and method for the production thereof |
| 08/29/2002 | WO2002066012A2 Amphoteric liposomes and the use thereof |
| 08/29/2002 | WO2002065992A2 A cell therapy method for the treatment of tumors |
| 08/29/2002 | WO2002065988A2 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 08/29/2002 | WO2002065986A2 Transporters comprising spaced arginine moieties |
| 08/29/2002 | WO2002065978A2 Functional agent for decomposing nicotine and method of preparing the same |
| 08/29/2002 | WO2002065859A1 Emulsions and aqueous dispersions of phytosterols |
| 08/29/2002 | WO2002042316A3 Pna analogues |
| 08/29/2002 | WO2002042273A3 Acid derivatives useful as serine protease inhibitors |
| 08/29/2002 | WO2002028867A3 Ethers of 7-desmethylrapamycin for use in immunosuppression |
| 08/29/2002 | WO2002028858A3 Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction |
| 08/29/2002 | WO2002024235A3 Prochelators of radiometal labeled molecules |
| 08/29/2002 | WO2002022795A3 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 08/29/2002 | WO2002020786A3 Kinase d interacting protein |
| 08/29/2002 | WO2002020723A3 Compositions and methods for targeting peptides in humans in vivo |
| 08/29/2002 | WO2002018383A3 Aza heterocyclic derivatives and their therapeutic use |
| 08/29/2002 | WO2002010403A3 Regulation of human phosphatidylinositol-specific phospholipase c-like enzyme |
| 08/29/2002 | WO2002008256A3 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 08/29/2002 | WO2002008241A3 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 08/29/2002 | WO2002002774A3 32626, a human udp-glycosyltransferase and uses thereof |
| 08/29/2002 | WO2002002525A3 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| 08/29/2002 | WO2002000227A3 Use of lanthanum compounds for the treatment of bone diseases |
| 08/29/2002 | WO2001096547A3 Human kinases |
| 08/29/2002 | WO2001095943A3 Prodrug compounds with an oligopeptide having an isoleucine residue |
| 08/29/2002 | WO2001091808A3 Bioconjugates of nanoparticles as radiopharmaceuticals |
| 08/29/2002 | WO2001087239A3 Methods of affecting laminin 5 processing |
| 08/29/2002 | WO2001085944A3 Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor |
| 08/29/2002 | WO2001082975A3 Membrane-permeant peptide complexes for medical imaging |
| 08/29/2002 | WO2001080888A3 Method for treatment of tumors using photodynamic therapy |
| 08/29/2002 | WO2001077338A3 Human protein kinases and protein kinase-like enzymes |
| 08/29/2002 | WO2001061055A3 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes |
| 08/29/2002 | WO2001060408A3 Microcompetiton and human disease |
| 08/29/2002 | WO2001057206A3 Method and reagent for the inhibition of checkpoint kinase-1 (chk 1) enzyme |
| 08/29/2002 | WO2001012584A3 Pharmaceutical compounds |
| 08/29/2002 | WO2001007481A9 Antitumor antibodies, proteins, and uses thereof |
| 08/29/2002 | WO2001005427A9 Psca: prostate stem cell antigen and uses thereof |
| 08/29/2002 | WO2001004629A9 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death |
| 08/29/2002 | WO2001000247A9 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 08/29/2002 | WO2000067746A9 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 08/29/2002 | WO2000061788A3 Poly(dipeptide) as a drug carrier |
| 08/29/2002 | WO2000059515A9 Immunomodulating polymers |
| 08/29/2002 | WO2000037502A9 Vascular endothelial cell growth factor antagonists and uses thereof |
| 08/29/2002 | WO2000034474A9 Growth factor homolog zvegf3 |
| 08/29/2002 | WO2000034447A9 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 08/29/2002 | WO2000010981A9 Quinazoline derivatives |
| 08/29/2002 | US20020120948 Modulating gene expression by regulation of cell proliferation; regulated transgene expression in lymphocytes by selective increase in the number of lymphocytes upon exposure to an antigen |
| 08/29/2002 | US20020120145 Inhibiting farnesyl protein transferase. |
| 08/29/2002 | US20020120137 FXR modulators |
| 08/29/2002 | US20020120123 Human vascular endothelial growth factor 2 |
| 08/29/2002 | US20020120121 Antisense therapy of cancer; Inhibitors of Apoptosis Proteins (IAPs) and an additional related antiapoptotic protein, NAIP; |
| 08/29/2002 | US20020120117 Polynucleotide that exhibits urothelial cell-specific transcriptional response element (TRE) activity; adenoviral vectors which replicate preferentially in urothelial cells; treating bladder cancer for example |
| 08/29/2002 | US20020120103 17 human secreted proteins |
| 08/29/2002 | US20020120100 Peptide transporters that specifically target certain cell types for the delivery of drugs and therapeutic agents |
| 08/29/2002 | US20020120099 Novel cyclic tetrapeptide derivatives and pharmaceutical uses thereof |
| 08/29/2002 | US20020119999 Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies |
| 08/29/2002 | US20020119996 Novel acetyloxymethyl esters and methods for using the same |
| 08/29/2002 | US20020119990 Liposomal camptothecins and uses thereof |
| 08/29/2002 | US20020119988 Modulators of TNF-alpha signaling |
| 08/29/2002 | US20020119981 Novel N-substituted urea inhibitors of farnesyl-protein transferase |
| 08/29/2002 | US20020119979 Cancer therapy |
| 08/29/2002 | US20020119977 Antitumor agents; antiinflammatory agents; analgesics; antipyretic agent |
| 08/29/2002 | US20020119975 Autoimmune disease; antiinflammatory agents; antiallergens; antiproliferative agents; anticancer agents |
| 08/29/2002 | US20020119967 Autoimmune diseases; administering phosphodiesterases inhibitor |
| 08/29/2002 | US20020119964 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase |
| 08/29/2002 | US20020119963 Fertility; antidiabetic agents |
| 08/29/2002 | US20020119961 Bridged piperazine derivatives |
| 08/29/2002 | US20020119960 Drug resistance therapy |
| 08/29/2002 | US20020119956 Using thalidomine |
| 08/29/2002 | US20020119955 Modified prodrug forms of AP/AMP |
| 08/29/2002 | US20020119953 Sickle cell anemia |
| 08/29/2002 | US20020119946 Formative agent of protein complex |
| 08/29/2002 | US20020119945 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 08/29/2002 | US20020119940 Gene expression and delivery systems and uses |
| 08/29/2002 | US20020119932 RGD-analog non-peptidic molecules having anti-adhesive, anti-migration and anti-proliferative effects |
| 08/29/2002 | US20020119931 Peptide inhibiting platelet derived growth factor (PDGF-BB) and fibroblast growth factor (bFGF) activity |
| 08/29/2002 | US20020119565 Isolation and use of solid tumor stem cells |
| 08/29/2002 | US20020119562 Method for selecting improved vectors |
| 08/29/2002 | US20020119548 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/29/2002 | US20020119519 Nucleotide sequences coding preferential polyeptide for use in the treatment of cancer, kidney and respiratory disorders |
| 08/29/2002 | US20020119504 Antibody or antigen-binding sequences for use in the treatment of inflammatory bowel disease |
| 08/29/2002 | US20020119502 Screening drugs for use in the treatment of mammary gland cancer; obtain animal, inject or orally administer anticarcinogeneic agent, monitor animal for development of cancer |
| 08/29/2002 | US20020119488 In vitro method for treating cancer; obtain stem cells, incubate with carriers specific for tumor cells, separate conjugate, purge blood cells and/or bone marrow |
| 08/29/2002 | US20020119479 Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of a variant GPIIIa and/or variant GPIIb allele |
| 08/29/2002 | US20020119473 Nucleotide sequence ligand for use in the detection diagnosis and treatment of cancer |
| 08/29/2002 | US20020119443 Screening preferential prodrugs for use in viral therapy; obtain target tissue, incubate with prodrug, monitor and evaluate prodrug activity in tissues |
| 08/29/2002 | US20020119202 For therapy of cancer and other angiogenic-dependent diseases |
| 08/29/2002 | US20020119198 For manufacture of a medicament for therapeutic treatment, such as steroidal, antifungal, antibacterial, or anticancer treatment |
| 08/29/2002 | US20020119189 Nucleosome-based anti-tumor compositions |
| 08/29/2002 | US20020119164 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 08/29/2002 | US20020119158 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 08/29/2002 | US20020119157 For cancer therapy |